Abbott study links CGM use in Type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk

Bitget2026/09/27 22:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Abbott flagged new real-world data linking continuous glucose monitoring use to fewer deaths in Type 2 diabetes patients on basal insulin.
Results will be presented at EASD starting Sept. 28, 2026, supporting broader adoption of Libre in a large insulin-treated population.
A separate observational analysis tied Libre use to fewer hospitalizations for acute diabetes events in Type 2 diabetes patients.
Abbott also plans to present additional FreeDM2 trial analyses showing faster, sustained improvements in glucose control following Libre 3 initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Abbott study links CGM use in Type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk

You may also like

Crypto prices